[{"address1": "321 Harrison Avenue", "address2": "11th Floor, Suite 1", "city": "Boston", "state": "MA", "zip": "02118", "country": "United States", "phone": "617 453 3596", "website": "https://www.pyxisoncology.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 44, "companyOfficers": [{"maxAge": 1, "name": "Dr. Lara S. Sullivan M.D., MBA", "title": "CEO, President, Chief Medical Officer & Director", "fiscalYear": 2023, "totalPay": 1209900, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Pamela Yanchik Connealy M.B.A.", "age": 62, "title": "CFO & COO", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 709700, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Balu N. Balasubramanian Ph.D.", "title": "Interim Chief Technology Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jan  Pinkas Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Charles T. Gombar Ph.D.", "title": "Senior Vice President of Portfolio & Program Management", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 6, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 10, "governanceEpochDate": 1746057600, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.1, "open": 1.1, "dayLow": 1.1, "dayHigh": 1.33, "regularMarketPreviousClose": 1.1, "regularMarketOpen": 1.1, "regularMarketDayLow": 1.1, "regularMarketDayHigh": 1.33, "payoutRatio": 0.0, "beta": 1.171, "forwardPE": -1.0588235, "volume": 1289445, "regularMarketVolume": 1289445, "averageVolume": 594619, "averageVolume10days": 677590, "averageDailyVolume10Day": 677590, "bid": 1.22, "ask": 1.3, "bidSize": 1, "askSize": 1, "marketCap": 78054104, "fiftyTwoWeekLow": 0.833, "fiftyTwoWeekHigh": 5.39, "priceToSalesTrailing12Months": 4.8342686, "fiftyDayAverage": 1.0701, "twoHundredDayAverage": 2.390925, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -29127078, "profitMargins": 0.0, "floatShares": 44339556, "sharesOutstanding": 61590400, "sharesShort": 7131225, "sharesShortPriorMonth": 6924016, "sharesShortPreviousMonthDate": 1741910400, "dateShortInterest": 1744675200, "sharesPercentSharesOut": 0.1158, "heldPercentInsiders": 0.23586, "heldPercentInstitutions": 0.39816, "shortRatio": 14.99, "shortPercentOfFloat": 0.1396, "impliedSharesOutstanding": 61947700, "bookValue": 2.014, "priceToBook": 0.62562066, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -77331000, "trailingEps": -1.32, "forwardEps": -1.19, "enterpriseToRevenue": -1.804, "enterpriseToEbitda": 0.465, "52WeekChange": -0.7076566, "SandP52WeekChange": 0.09765589, "quoteType": "EQUITY", "currentPrice": 1.26, "targetHighPrice": 8.0, "targetLowPrice": 5.0, "targetMeanPrice": 6.0, "targetMedianPrice": 5.5, "recommendationMean": 1.66667, "recommendationKey": "buy", "numberOfAnalystOpinions": 4, "totalCash": 126931000, "totalCashPerShare": 2.061, "ebitda": -62588000, "totalDebt": 20200000, "quickRatio": 7.179, "currentRatio": 7.491, "totalRevenue": 16146000, "debtToEquity": 16.729, "revenuePerShare": 0.276, "returnOnAssets": -0.24768999, "returnOnEquity": -0.62755, "grossProfits": 15671000, "freeCashflow": -33791248, "operatingCashflow": -57672000, "grossMargins": 0.97058, "ebitdaMargins": 0.0, "operatingMargins": -4.06107, "financialCurrency": "USD", "symbol": "PYXS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "postMarketTime": 1746229674, "regularMarketTime": 1746216001, "shortName": "Pyxis Oncology, Inc.", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 594619, "fiftyTwoWeekLowChange": 0.427, "fiftyTwoWeekLowChangePercent": 0.512605, "fiftyTwoWeekRange": "0.833 - 5.39", "fiftyTwoWeekHighChange": -4.13, "fiftyTwoWeekHighChangePercent": -0.7662338, "fiftyTwoWeekChangePercent": -70.76566, "earningsTimestamp": 1742297400, "earningsTimestampStart": 1747053000, "earningsTimestampEnd": 1747398600, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.32, "epsForward": -1.19, "epsCurrentYear": -1.276, "priceEpsCurrentYear": -0.9874608, "fiftyDayAverageChange": 0.18990004, "fiftyDayAverageChangePercent": 0.17746009, "twoHundredDayAverageChange": -1.1309249, "twoHundredDayAverageChangePercent": -0.4730073, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-10-08", "averageAnalystRating": "1.7 - Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1633699800000, "postMarketChangePercent": 0.0, "postMarketPrice": 1.26, "postMarketChange": 0.0, "regularMarketChange": 0.15999997, "regularMarketDayRange": "1.1 - 1.33", "marketState": "CLOSED", "exchange": "NMS", "messageBoardId": "finmb_629268721", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 14.545451, "regularMarketPrice": 1.26, "longName": "Pyxis Oncology, Inc.", "displayName": "Pyxis Oncology", "trailingPegRatio": null, "__fetch_time": "2025-05-03"}]